Rapid antibody response to influenza vaccination in 'at risk' groups

Vaccine

Volumn 18, Issue 21, 2000, Pages 2307-2311

  Lambkin, R ^a   Oxford, J S ^a   Biao, L ^a   Al Jabri, A ^a   Fleming, D ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

Antibody; Influenza; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TITRIMETRY; URBAN AREA; VIRUS INHIBITION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; MIDDLE AGED; RISK; TIME FACTORS; VACCINATION;

EID: 0034093703     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00437-5     Document Type: Article

References (26)

1. Stuart-Harris CH, Schild GC, Oxford JS. Influenza, the viruses and the disease. In: Arnold E, editor. London, 1984.
2. Perrotta D., Decker M., Glezen W. Acute respiratory disease hospitalisation as a measure of impact of epidemic influenza. American Journal of Epidemiology. 122:1985;468-476.
3. Glezen W, Decker M, Perrotta D. Survey of underlying conditions of persons hospitalised with acute respiratory disease during influenza epidemics in Houston, 1978-1981. American Review of Respiratory Diseases 1987;138.
4. Fleming D. The impact of three influenza epidemics on primary care in England and Wales. PharmacoEconomics. 9:1996;38-45.
5. Ashley J., Smith T., Dunnell K. Deaths in Great Britain associated with the influenza epidemic of 1989/90. Population Trends. 65:1991;16-20.
6. Baker W., Rauberta R., Menegus M. Case control study of influenza vaccine effectiveness in preventing pneumonia hospitalisation among older persons, Monroe County, New York, 1989-1992. Hanoun C., Kendal A., Klenk H., Ruben F. Options for the control of influenza II. 1993;Elseviers Science Publishers, Amsterdam.
7. Mullooly J.P., Bennett M.D., Horbrook M.C. Influenza vaccination programs for elderly person: Cost effectiveness in a Health Maintenance Organisation. Annals of Internal Medicine. 121:1994;947-952.
8. Fleming D.M., Watson J.M., Nicholas S., Smith G.E., Swan A.V. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiology and Infection. 115:1995;581-589.
9. Nicholson K., Snacken A., Palache A. Influenza immunisation policies in Europe and the United States. Vaccine. 13:1995;365-369.
10. Bradley M., Sheldon T. Influenza vaccine and older people: an evidence based policy. British Journal of General Practice. 47:1997;271-272.
11. Barker W.H., Mullooly J.P. Influenza vaccination of elderly persons: reductions in pneumonia and influenza hospitalisation and deaths. JAMA. 244:1980;2547-2549.
12. Ahmed A.H., Nicholson K.G., Nguyen Van Tam J.S. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet. 346:1995;591-595.
13. Evans M.R. Monitoring influenza immunisation uptake in nursing homes. Communicable Disease Report. 6:1996;170-174.
14. Nichol K.L., Margolis K.L., Wuorenma J., Sternberg von T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New England Journal of Medicine. 22:1994;778-784.
15. Cox R.J., Brokstad K.A., Zuckerman M.A., Wood J.M., Haaheim L.R., Oxford J.S. An early humoral immune response in peripheral blood following parental inactivated influenza vaccination. Vaccine. 12:1994;993-999.
16. Brokstad K.A., Cox R.J., Major D., Wood J.M., Haaheim L.R. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine. 13:1995;1522-1528.
17. Brokstad K.A., Cox R.J., Oxford J.S., Haaheim L.R. IgA, IgA subclasses and secretory component levels in oral fluid collected from subjects after parental influenza vaccination. Journal of Infectious Diseases. 171:1995;1072-1074. [letter].
18. Committee on influenza and other respiratory virus vaccines. Trials of an Asian influenza vaccine. British Medical Journal. 1958:415-418.
19. Zuckerman M., Wood J., Chakraverty P., Taylor J., Heath A., Oxford J. Serological response in volunteers to inactivated trivalent subunit influenza vaccine: Antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. Journal of Medical Virology. 33:1991;133-137.
20. Remarque E.J., Cools H.J., Boere T.J., van der Klis R.J., Masurel N., Ligthart G.J. Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home. British Medical Journal. 312:1996;1015.
21. Potter C.W., McLaren C., Jennings R. Assessment of resistance to influenza virus infection in animal models. Developments in Biological Standardization. 28:1975;307-318.
22. Kendal A., Periera M., Skehel J. Concepts and procedures for laboratory based influenza surveillance. 1982;US Department of Health and Human Services, Washington, DC.
23. Hobson D., Curry R., Beare A., Ward-Gardener A. The role of serum haemagglutination inhibition antibody in protection against challenge infection with influenza A and B viruses. Journal of Hygiene. 94:1972;87-95.
24. 1) virus variants with monoclonal antibodies. Journal of General Virology. 67:1986;2247-2251.
25. 5 haemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity. Journal of Virology. 63:1989;3453-3458.
26. Kruskall M.S., Alper C.A., Awdel Z., Tunis Z., Marcus-Bagley D. The immune response to Hepatitis B vaccine in human inheritance patterns in families. Journal of Experimental Medicine. 175:1992;495-502.